DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• SOX11, a neural transcription factor, plays a role in tumorigenesis and exhibits precise transcriptional regulation.
• Investigating epigenetic differences in SOX11 expression between normal and cancerous cells is crucial for understanding its role in malignancy.

Purpose of the Study:

• To explore epigenetic regulation of SOX11 expression in normal versus neoplastic cells.
• To investigate the potential of re-expressing SOX11 using histone deacetylase (HDAC) or EZH2 inhibitors.

Main Methods:

• Assessed DNA methylation using bisulfite sequencing and pyrosequencing.
• Evaluated H3K27me3 enrichment via ChIP-qPCR.
• Utilized HDAC inhibitors (Vorinostat, trichostatin A) to induce SOX11 expression.

Main Results:

• Non-malignant cells show low SOX11 promoter methylation and high H3K27me3.
• B-cell lineage cancers exhibit de novo SOX11 promoter methylation; solid tumors show variable methylation.
• HDAC inhibitors successfully induced SOX11 expression in cancer cells with low SOX11 promoter methylation.

Conclusions:

• SOX11 is epigenetically regulated by repressive histone marks in normal cells.
• Neoplastic SOX11 regulation involves complex DNA methylation and histone modifications.
• Re-expressing SOX11 in non-methylated cancer cells via HDAC inhibitors is clinically relevant and demonstrated efficacy.